Lundbeck Ready To File Alzheimer’s Agitation Treatment, A Potential First

Filing Expected In Q4

 
• By Andrew McConaghie
  
Lundbeck
Lundbeck and Otsuka are close to filing the drug for Alzheimer's agitation, which could see it become the first licensed therapy by 2023.

More from Clinical Trials

More from R&D